Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Avita Medical has shown promising financial trends, including an 11% year-over-year revenue increase, reaching $71.6 million for the full year, and an improvement in cash usage that decreased sequentially to approximately $5.1 million. The company's management has set revenue guidance for 2026 between $80 million and $85 million, indicating expectations of growth in the range of 12% to 19% driven by strategic initiatives and deeper market penetration. Additionally, Avita's recent refinancing of debt has bolstered its balance sheet, enhancing its capacity to support sustained growth and operational execution in the coming years.

Bears say

Avita Medical reported a net loss of $11.6 million, or $0.38 per share, which reflects a slight improvement from the previous year's loss of $11.6 million, or $0.44 per share; however, this does not indicate a strong financial performance. The company’s revenue structure is concerning, with only approximately $3.97 million guaranteed over a 10-year term, which highlights a significant reliance on optional procurement that could create revenue uncertainty. This leads to a negative outlook, as the reliance on a single product, along with back-end loaded revenue from a government preparedness contract, undermines the company's overall financial stability and growth potential.

RCEL has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.